Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease

Molecular Medicine Today

Volumn 4, Issue 4, 1998, Pages 151-157

  Ray, William J ^a   Ashall, Frank ^a   Goate, Alison M ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; NERVE CELL LESION; PATHOGENESIS; REVIEW; SENILE PLAQUE;

AGE OF ONSET; AGED; ALLELES; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; BUTYRYLCHOLINESTERASE; CALCIUM; CARDIOVASCULAR DISEASES; DISEASE SUSCEPTIBILITY; GENES, DOMINANT; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIA; NEUROFIBRILLARY TANGLES; NEUROGLIA; NEUROTOXINS; OXIDATIVE STRESS; PRESENILIN-1; PRESENILIN-2; RISK FACTORS; SENILE PLAQUES;

EID: 0031969718     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01229-5     Document Type: Review

References (39)

1. McKhann G.et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force. Neurology. 34:1984;939-944.
2. Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56:1997;321-339.
3. Selkoe D.J. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17:1994;489-517.
4. Lendon C.L.et al. Exploring the etiology of Alzheimer disease using molecular genetics. J. Am. Med. Assoc. 277:1997;825-831.
5. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 1996:1996;53-77.
6. Mattson M.P. Calcium and neuronal injury in Alzheimer's disease. Contributions of beta-amyloid protein mismetabolism, free radicals, and metabolic compromise. Ann. New York Acad. Sci. 747:1994;50-76.
7. Haass C. Presenilins: genes for life and death. Neuron. 18:1997;687-690.
8. Farrer L.A.et al. Effects of age, gender, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease - a meta-analysis. J. Am. Med. Assoc. 278:1997;1345-1356.
9. Bales K.R.et al. Lack of apolipoprotein E dramatically reduces amyloid β-deposition. Nat. Genet. 17:1997;263-264.
10. Bullido M.J.et al. Polymorphism in the transcriptional regulatory region of apolipoprotein E gene associated with risk for dementia of the Alzheimer type. Nat. Genet. 18:1998;67-71.
11. Rubinzstein D.C. The genetics of Alzheimer's disease. Progr. Neurobiol. 52:1997;447-454.
12. Lehmann D.J.et al. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum. Mol. Genet. 6:1997;1933-1936.
13. Pericak-Vance M.A.et al. Complete genomic screen in late onset familial Alzheimer disease - evidence for a new locus on chromosome 12. J. Am. Med. Assoc. 278:1997;1237-1241.
14. Tamaoka A.et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 141:1996;65-68.
15. Scheuner D.et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870.
16. Vinter H.V.et al. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 6:1996;179-195.
17. Slooter A.J.et al. Apolipoprotein E ε4 and the risk of dementia with stroke. J. Am. Med. Assoc. 277:1997;818-821.
18. Contois J.H.et al. The underlying molecular mechanisms of apolipoprotein E polymorphism: relationship to lipid disorders, cardiovascular disease, and Alzheimer's disease. Clin. Lab. Med. 16:1996;105-123.
19. Grady D.et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117:1992;1016-1037.
20. Bourassa P.A.K.et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10022-10027.
21. Snowdon D.A.et al. Brain infarction and the clinical expression of Alzheimer disease. J. Am. Med. Assoc. 277:1997;813-817.
22. Longstreth W.T.et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. Stroke. 27:1996;1274-1282.
23. Liao D.et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. Stroke. 27:1996;2262-2270.
24. Rogers J.et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686.
25. McRae A.et al. Microglia in neurodegenerative disorders: emphasis on Alzheimer's disease. Gerontology. 43:1997;95-108.
26. Curran M.et al. HLA-DR antigens associated with major genetic risk for late-onset Alzheimer's disease. Neuroreport. 8:1997;1467-1469.
27. Payami H.et al. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology. 49:1997;512-518.
28. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
29. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.
30. Shearman M.S.et al. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc. Natl. Acad. Sci. U. S. A. 91:1994;1470-1474.
31. Edland S.D.et al. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology. 47:1996;254-256.
32. Duara R.et al. A comparison of familial and sporadic Alzheimer's disease. Neurology. 43:1993;1377-1384.
33. Hutchin T., Cortipassi G. A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 92:1995;6892-6895.
34. Davis R.E.et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 91:1993;1470-1474.
35. Wragg M.A.et al. No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. Neurosci. Lett. 201:1996;509-512.
36. Sano M.et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Comparative Study. New Engl. J. Med. 336:1997;1245-1247.
37. Weisgraber K.H., Mahley R.W. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10:1996;1485-1494.
38. Scheuner D.et al. Secreted amyloid-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870.
39. Eckman C.B.et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A42(43). Hum. Mol. Genet. 6:1997;2087-2089.